Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by PLITheOneon Aug 11, 2021 8:54am
32 Views
Post# 33683916

RE:RE:Bought back IN

RE:RE:Bought back IN
astrogrognon wrote: Hi ORTsnort, The employees have lost all their stock options given as "bonus". We can think that actions that were given to senior employees worth now nothing.  Most of the money raised last spring has been used to pay the suppliers.  Not much left for continuying business as we know. No expansion projects has been announced to increase the production capacity. There is still a serious discrenpancy between the salaries paid for certain board members  and the regular employees. The latter ones could not afford to buy rights while the big guys were getting thousands of new actions, something that added 14 millions as expenses if i understand correctly.   So employees are pissed because they have worked there thinking that they would get some of the profit sometimes but they've lost whatever they had.  Employees are stressed because if the plasminogen business is sold eventually by a lazard "deal" as part of the "monitizing of assets outside small molecules, they will loose their jobs becasue the equipments will be moved to a different city. No plasminogen means no revenu from it so bye bye that profit.  At this moment, it is cheaper for a big pharma to buy the whole company then trying to make deals. Why make deals when you can buy the whole thing? Also I doubt that an investment company knows how to run well a pharma company. That is not their core business so they can bring little other then cash and the cash comes from the retail investors anyway at this moment.  Yes it is crazy.


<< Previous
Bullboard Posts
Next >>